PDE4A and polycystic ovary syndrome: Considering the innovative concept that grasps selective PDE4 inhibition as a potential new therapeutic target in obesity associated populations, in the present study we used an upgraded design to further elucidate the potential effect of roflumilast in treatment-naïve obese PCOS population.